Anavex Life Sciences Corp (AVXL)

[falconer66a]

Anavex in the Insomnia Treatment Market

I just read today's Anavex U.S. patent application, where a patent for "A2-73 AS A THERAPEUTIC FOR INSOMNIA, ANXIETY AND AGITATION" is applied for.

Of course, insomnia, anxiety, and agitation are common complications of Alzheimer's disease, making things difficult for both people with Alzheimer's and their caregivers. Being able to therapeutically obviate these behavioral anomalies with Anavex's sigma-1 receptor molecules would be a major accomplishment.

The market for this use of Anavex 2-73 (blarcamesine) is gigantic. The vast majority of Alzheimer's patients suffer from insomnia, anxiety, and/or agitation.

But, of course, insomnia is not restricted to Alzheimer's patients. About one in ten Americans has chronic (long-term, persisting) insomnia, which pathologically disrupts normal living and mental and physical health.
https://cfah.org/sleep-statistics/

Presently, there are a number of prescription anti-insomnia drugs. But they have many deleterious side effects, which can be as bad or worse than the insomnia that is being treated.

In every human clinical trial of Anavex 2-73 (blarcamesine) adverse events ("side effects") have been either absent altogether, or involved only moderate to slight dizziness or headache that did not persist. The Anavex sigma-1 receptor agonists, such as Anavex 2-73 in every case have proven to be very safe and well-tolerated.

Consequently, as provided for in this patent application, there is the prospect that Anavex Life Sciences Corp can be a major producer of exceptional anti-insomnia drugs. The market for such will be billions of dollars.